SERGEY PUZYREVSKIY PRESENTED PLANS OF FAS LEGISLATIVE WORK TO THE STATE DUMA
Head of the intra-fraction group of the “United Russia” party, Viktor Kidyaev took part in the meeting
Deputy Head of FAS Sergey Puzyrevskiy pointed out that recently policy documents on competition development were synchronized at several levels.
“The first level is the Order of the President of the Russian Federation on the main directions of the state policy for competition development. The document approved 2018–2020 National Competition Development Plan, which is a mid-term plan for its development at the federal level with the key targets for the next three years”, reported Deputy Head of FAS.
“The second level includes orders given by the President of Russia following the State Council the Russian Federation, and the next level is the Road Map of the Government of the Russian Federation for Competition Development by sectors of the economy”, continued Sergey Puzyrevskiy.
“Our regions actively supported the goals of advancing competition. We held talks with all regions and signed Agreements on Cooperation between FAS and the subjects of the Russian Federation. In coordination with FAS, practically all regions approved no less than 33 targets for competition development out of 41 suggested by State Council the Russian Federation”, added Deputy Head of FAS.
FAS legislative initiatives are a special block of work. Six draft laws are submitted to the RF Government, including the fifth “digital” antimonopoly package, on reforming natural monopolies and the basic principles of government price (tariff) regulation.
“Another draft law that bans unitary enterprises on competition markets has passed the first reading in the State Duma. Considering the comments to the draft law give by the State Duma and the Federation Council, the RF Government gave additional amendments for the second reading. Hopefully, the State Duma will also consider than in the near future”, emphasized Sergey Puzyrevskiy.
Another item on the agenda was medicinal drug supply related to incorrect reference price estimates. FAS has analyzed such prices based on the data from the drug catalogue of the information-and-analytical system for procurement monitoring.
One of the main errors is estimating reference prices of the same group of drugs based on the difference measurement units. For example, as it may be seen from the details of estimating the reference price, both prices per 1 mg and per 1 capsule are used as a consumer unit, which leads to incorrect calculations.
Sergey Puzyrevskiy informed that FAS had sent a letter to the Ministry of Healthcare on the need to make amendments to the Procedure for determining the initial (maximum) contract price concluded with a single supplier in procurement of medicines for medical purposes.
The drat order of the Ministry of Healthcare on amending the procedure is published on regulation.gov.ru, according to which mandatory use of reference prices is not used prior to entering the relevant data in the Unified Information System on procurement.